Adds a statutory definition of “direct-to-consumer advertising” to the misbranding provisions of the Federal Food, Drug, and Cosmetic Act and makes that definition apply to drugs approved under section 505 (new drug approvals) or licensed under section 351 (biologics). The change takes effect 30 days after enactment and applies to covered drugs regardless of when they were approved or licensed.